Do analysts recommend ENSC or VCNX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ensysce Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Vaccinex 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is ENSC or VCNX more profitable?

Vaccinex has a net margin of 0.00% compared to Ensysce Biosciences' net margin of -280.53%. Vaccinex's return on equity of 0.00% beat Ensysce Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Ensysce Biosciences -280.53% -2,550.30% -320.49% Vaccinex N/A N/A -383.58%

Do analysts rate VCNX or TRAW?

Traws Pharma has a consensus target price of $1.00, suggesting a potential upside of 100.00%. Given Traws Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Traws Pharma is more favorable than Vaccinex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vaccinex 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Traws Pharma 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.80

Which has better earnings and valuation, VCNX or TRAW?

Traws Pharma has higher revenue and earnings than Vaccinex. Traws Pharma is trading at a lower price-to-earnings ratio than Vaccinex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vaccinex $388K 6.70 -$20.25M -$48.27 N/A Traws Pharma $2.79M 2.75 $9.17M -$1.74 N/A

Is VCNX or TRAW more profitable?

Vaccinex's return on equity of 0.00% beat Traws Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Vaccinex N/A N/A -383.58% Traws Pharma N/A -23,868.92% -165.52%

Which has preferable earnings & valuation, VCNX or OBSV?

Vaccinex has higher revenue and earnings than ObsEva. Vaccinex is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vaccinex $388K 6.70 -$20.25M -$48.27 N/A ObsEva N/A N/A -$58.38M -$0.92 N/A

Is VCNX or OBSV more profitable?

Vaccinex's return on equity of 0.00% beat ObsEva's return on equity. Company Net Margins Return on Equity Return on Assets Vaccinex N/A N/A -383.58% ObsEva N/A -416.36% -92.01%

Do analysts recommend VCNX or ACXP?

Acurx Pharmaceuticals has a consensus target price of $31.00, indicating a potential upside of 2,186.14%. Given Acurx Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Acurx Pharmaceuticals is more favorable than Vaccinex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vaccinex 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Acurx Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is VCNX or ACXP more profitable?

Vaccinex's return on equity of 0.00% beat Acurx Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Vaccinex N/A N/A -383.58% Acurx Pharmaceuticals N/A -124.73% -87.48%

Do analysts rate VCNX or CNSP?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vaccinex 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 CNS Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is VCNX or CNSP more profitable?

Vaccinex's return on equity of 0.00% beat CNS Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Vaccinex N/A N/A -383.58% CNS Pharmaceuticals N/A -204.25% -141.87%

Vaccinex (VCNX) Competitors

$1.00 0.00 (0.00%)

As of 09/23/2026 09:30 AM Eastern

Compare

VCNX vs. ENSC, TRAW, OBSV, ACXP, and CNSP

Should you buy Vaccinex stock or one of its competitors? Vaccinex's main competitors and comparable companies include Ensysce Biosciences (ENSC), Traws Pharma (TRAW), ObsEva (OBSV), Acurx Pharmaceuticals (ACXP), and CNS Pharmaceuticals (CNSP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Vaccinex compare to Ensysce Biosciences?

Ensysce Biosciences (NASDAQ:ENSC) and Vaccinex (NASDAQ:VCNX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, profitability, valuation, dividends and institutional ownership.

5.6% of Ensysce Biosciences shares are owned by institutional investors. Comparatively, 50.1% of Vaccinex shares are owned by institutional investors. 2.8% of Ensysce Biosciences shares are owned by insiders. Comparatively, 51.5% of Vaccinex shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Vaccinex has a net margin of 0.00% compared to Ensysce Biosciences' net margin of -280.53%. Vaccinex's return on equity of 0.00% beat Ensysce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ensysce Biosciences	-280.53%	-2,550.30%	-320.49%
Vaccinex	N/A	N/A	-383.58%

Ensysce Biosciences has higher revenue and earnings than Vaccinex. Ensysce Biosciences is trading at a lower price-to-earnings ratio than Vaccinex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ensysce Biosciences	$5.07M	1.55	-$10.18M	-$2.76	N/A
Vaccinex	$388K	6.70	-$20.25M	-$48.27	N/A

In the previous week, Ensysce Biosciences had 1 more articles in the media than Vaccinex. MarketBeat recorded 1 mentions for Ensysce Biosciences and 0 mentions for Vaccinex. Ensysce Biosciences' average media sentiment score of 0.00 equaled Vaccinex'saverage media sentiment score.

Company	Overall Sentiment
Ensysce Biosciences	Neutral
Vaccinex	Neutral

Ensysce Biosciences has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market. Comparatively, Vaccinex has a beta of 1.1, meaning that its stock price is 10% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ensysce Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Vaccinex	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Vaccinex beats Ensysce Biosciences on 7 of the 13 factors compared between the two stocks.

How does Vaccinex compare to Traws Pharma?

Vaccinex (NASDAQ:VCNX) and Traws Pharma (NASDAQ:TRAW) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Traws Pharma has a consensus target price of $1.00, suggesting a potential upside of 100.00%. Given Traws Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Traws Pharma is more favorable than Vaccinex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaccinex	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Traws Pharma	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Vaccinex's return on equity of 0.00% beat Traws Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaccinex	N/A	N/A	-383.58%
Traws Pharma	N/A	-23,868.92%	-165.52%

Vaccinex has a beta of 1.1, suggesting that its share price is 10% more volatile than the broader market. Comparatively, Traws Pharma has a beta of 1.6, suggesting that its share price is 60% more volatile than the broader market.

In the previous week, Traws Pharma had 2 more articles in the media than Vaccinex. MarketBeat recorded 2 mentions for Traws Pharma and 0 mentions for Vaccinex. Vaccinex's average media sentiment score of 0.00 equaled Traws Pharma'saverage media sentiment score.

Company	Overall Sentiment
Vaccinex	Neutral
Traws Pharma	Neutral

50.1% of Vaccinex shares are held by institutional investors. Comparatively, 8.0% of Traws Pharma shares are held by institutional investors. 51.5% of Vaccinex shares are held by insiders. Comparatively, 7.6% of Traws Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Traws Pharma has higher revenue and earnings than Vaccinex. Traws Pharma is trading at a lower price-to-earnings ratio than Vaccinex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaccinex	$388K	6.70	-$20.25M	-$48.27	N/A
Traws Pharma	$2.79M	2.75	$9.17M	-$1.74	N/A

Summary

Traws Pharma beats Vaccinex on 8 of the 13 factors compared between the two stocks.

How does Vaccinex compare to ObsEva?

Vaccinex (NASDAQ:VCNX) and ObsEva (NASDAQ:OBSV) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, dividends, analyst recommendations, earnings, risk, profitability and valuation.

Vaccinex's return on equity of 0.00% beat ObsEva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaccinex	N/A	N/A	-383.58%
ObsEva	N/A	-416.36%	-92.01%

Vaccinex has a beta of 1.1, suggesting that its share price is 10% more volatile than the broader market. Comparatively, ObsEva has a beta of 0.68, suggesting that its share price is 32% less volatile than the broader market.

50.1% of Vaccinex shares are owned by institutional investors. Comparatively, 17.5% of ObsEva shares are owned by institutional investors. 51.5% of Vaccinex shares are owned by company insiders. Comparatively, 14.4% of ObsEva shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Vaccinex's average media sentiment score of 0.00 equaled ObsEva'saverage media sentiment score.

Company	Overall Sentiment
Vaccinex	Neutral
ObsEva	Neutral

Vaccinex has higher revenue and earnings than ObsEva. Vaccinex is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaccinex	$388K	6.70	-$20.25M	-$48.27	N/A
ObsEva	N/A	N/A	-$58.38M	-$0.92	N/A

Summary

Vaccinex beats ObsEva on 6 of the 9 factors compared between the two stocks.

How does Vaccinex compare to Acurx Pharmaceuticals?

Vaccinex (NASDAQ:VCNX) and Acurx Pharmaceuticals (NASDAQ:ACXP) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and profitability.

Acurx Pharmaceuticals has a consensus target price of $31.00, indicating a potential upside of 2,186.14%. Given Acurx Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Acurx Pharmaceuticals is more favorable than Vaccinex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaccinex	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Acurx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Vaccinex's return on equity of 0.00% beat Acurx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaccinex	N/A	N/A	-383.58%
Acurx Pharmaceuticals	N/A	-124.73%	-87.48%

50.1% of Vaccinex shares are held by institutional investors. Comparatively, 11.5% of Acurx Pharmaceuticals shares are held by institutional investors. 51.5% of Vaccinex shares are held by insiders. Comparatively, 6.5% of Acurx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Vaccinex's average media sentiment score of 0.00 equaled Acurx Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Vaccinex	Neutral
Acurx Pharmaceuticals	Neutral

Acurx Pharmaceuticals has lower revenue, but higher earnings than Vaccinex. Acurx Pharmaceuticals is trading at a lower price-to-earnings ratio than Vaccinex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaccinex	$388K	6.70	-$20.25M	-$48.27	N/A
Acurx Pharmaceuticals	N/A	N/A	-$7.97M	-$2.69	N/A

Vaccinex has a beta of 1.1, suggesting that its share price is 10% more volatile than the broader market. Comparatively, Acurx Pharmaceuticals has a beta of -2.02, suggesting that its share price is 302% less volatile than the broader market.

Summary

Vaccinex and Acurx Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.

How does Vaccinex compare to CNS Pharmaceuticals?

Vaccinex (NASDAQ:VCNX) and CNS Pharmaceuticals (NASDAQ:CNSP) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, media sentiment, risk, dividends, earnings and institutional ownership.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaccinex	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

50.1% of Vaccinex shares are held by institutional investors. Comparatively, 14.0% of CNS Pharmaceuticals shares are held by institutional investors. 51.5% of Vaccinex shares are held by insiders. Comparatively, 1.8% of CNS Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Vaccinex has a beta of 1.1, indicating that its share price is 10% more volatile than the broader market. Comparatively, CNS Pharmaceuticals has a beta of 3.06, indicating that its share price is 206% more volatile than the broader market.

Vaccinex's return on equity of 0.00% beat CNS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaccinex	N/A	N/A	-383.58%
CNS Pharmaceuticals	N/A	-204.25%	-141.87%

CNS Pharmaceuticals has lower revenue, but higher earnings than Vaccinex. CNS Pharmaceuticals is trading at a lower price-to-earnings ratio than Vaccinex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaccinex	$388K	6.70	-$20.25M	-$48.27	N/A
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$23.59	N/A

In the previous week, Vaccinex's average media sentiment score of 0.00 equaled CNS Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Vaccinex	Neutral
CNS Pharmaceuticals	Neutral

Summary

Vaccinex and CNS Pharmaceuticals tied by winning 5 of the 10 factors compared between the two stocks.

Get Vaccinex News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VCNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VCNX vs. The Competition

Export

Metric	Vaccinex	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.60M	$12.62B	$7.28B	$13.01B
Dividend Yield	N/A	2.63%	2.52%	12.57%
P/E Ratio	-0.02	797.33	274.92	25.63
Price / Sales	6.70	852.31	673.28	90.00
Price / Cash	N/A	88.64	77.80	52.76
Price / Book	-0.39	10.60	10.34	6.27
Net Income	-$20.25M	$2.84B	$3.49B	$360.12M
7 Day Performance	N/A	-0.78%	-1.13%	-0.31%
1 Month Performance	-4.76%	-1.63%	-3.55%	-3.67%
1 Year Performance	69.49%	2.51%	14.81%	5.14%

Vaccinex Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VCNX Vaccinex	N/A	$1.00 flat	N/A	+70.1%	$2.60M	$388K	N/A	40
ENSC Ensysce Biosciences	0.7498 of 5 stars	$0.46 +1.8%	N/A	-80.5%	$8.87M	$5.07M	N/A	10	News Coverage
TRAW Traws Pharma	1.3378 of 5 stars	$0.53 -0.6%	$1.00 +88.7%	-73.2%	$8.15M	$2.79M	N/A	17	News Coverage
OBSV ObsEva	N/A	N/A	N/A	N/A	$7.94M	N/A	N/A	50
ACXP Acurx Pharmaceuticals	2.0547 of 5 stars	$1.41 +1.8%	$31.00 +2,106.4%	-66.5%	$7.81M	N/A	N/A	3

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VCNX) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vaccinex (VCNX) Competitors

VCNX vs. ENSC, TRAW, OBSV, ACXP, and CNSP

How does Vaccinex compare to Ensysce Biosciences?

Summary

How does Vaccinex compare to Traws Pharma?

Summary

How does Vaccinex compare to ObsEva?

Summary

How does Vaccinex compare to Acurx Pharmaceuticals?

Summary

How does Vaccinex compare to CNS Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VCNX vs. The Competition

Vaccinex Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vaccinex (VCNX) Competitors

VCNX vs. ENSC, TRAW, OBSV, ACXP, and CNSP

How does Vaccinex compare to Ensysce Biosciences?

Do insiders & institutionals hold more shares of ENSC or VCNX?

Is ENSC or VCNX more profitable?

Which has better earnings & valuation, ENSC or VCNX?

Does the media prefer ENSC or VCNX?

Which has more volatility and risk, ENSC or VCNX?

Do analysts recommend ENSC or VCNX?

Summary

How does Vaccinex compare to Traws Pharma?

Do analysts rate VCNX or TRAW?

Is VCNX or TRAW more profitable?

Which has more volatility & risk, VCNX or TRAW?

Does the media refer more to VCNX or TRAW?

Do insiders & institutionals hold more shares of VCNX or TRAW?

Which has better earnings and valuation, VCNX or TRAW?

Summary

How does Vaccinex compare to ObsEva?

Is VCNX or OBSV more profitable?

Which has more volatility & risk, VCNX or OBSV?

Do institutionals & insiders have more ownership in VCNX or OBSV?

Does the media prefer VCNX or OBSV?

Which has preferable earnings & valuation, VCNX or OBSV?

Summary

How does Vaccinex compare to Acurx Pharmaceuticals?

Do analysts recommend VCNX or ACXP?

Is VCNX or ACXP more profitable?

Do institutionals and insiders believe in VCNX or ACXP?

Does the media refer more to VCNX or ACXP?

Which has higher earnings and valuation, VCNX or ACXP?

Which has more volatility & risk, VCNX or ACXP?

Summary

How does Vaccinex compare to CNS Pharmaceuticals?

Do analysts rate VCNX or CNSP?

Do institutionals & insiders hold more shares of VCNX or CNSP?

Which has more volatility & risk, VCNX or CNSP?

Is VCNX or CNSP more profitable?

Which has stronger earnings & valuation, VCNX or CNSP?

Does the media prefer VCNX or CNSP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VCNX vs. The Competition

Vaccinex Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools